IN2014DN08721A - - Google Patents

Info

Publication number
IN2014DN08721A
IN2014DN08721A IN8721DEN2014A IN2014DN08721A IN 2014DN08721 A IN2014DN08721 A IN 2014DN08721A IN 8721DEN2014 A IN8721DEN2014 A IN 8721DEN2014A IN 2014DN08721 A IN2014DN08721 A IN 2014DN08721A
Authority
IN
India
Prior art keywords
antibodies
present
regions
modified
contain
Prior art date
Application number
Other languages
English (en)
Inventor
Jay M Short
Hwai Wen Chang
Gerhard Frey
Original Assignee
Bioatla Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioatla Llc filed Critical Bioatla Llc
Publication of IN2014DN08721A publication Critical patent/IN2014DN08721A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IN8721DEN2014 2012-04-27 2013-04-26 IN2014DN08721A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261639729P 2012-04-27 2012-04-27
PCT/US2013/038538 WO2013163630A1 (fr) 2012-04-27 2013-04-26 Régions modifiées d'anticorps et leurs utilisations

Publications (1)

Publication Number Publication Date
IN2014DN08721A true IN2014DN08721A (fr) 2015-05-22

Family

ID=49483948

Family Applications (1)

Application Number Title Priority Date Filing Date
IN8721DEN2014 IN2014DN08721A (fr) 2012-04-27 2013-04-26

Country Status (13)

Country Link
US (2) US20150065690A1 (fr)
EP (2) EP3470433B1 (fr)
JP (1) JP6470170B2 (fr)
KR (2) KR20200037434A (fr)
CN (1) CN104428317B (fr)
AU (3) AU2013251309B2 (fr)
BR (1) BR112014026740B1 (fr)
CA (1) CA2871807C (fr)
HK (1) HK1207654A1 (fr)
IN (1) IN2014DN08721A (fr)
MX (2) MX382840B (fr)
RU (1) RU2014147741A (fr)
WO (1) WO2013163630A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2913205T3 (es) * 2014-05-13 2022-06-01 Bioatla Inc Proteínas biológicas activas condicionalmente
FR3038517B1 (fr) * 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
JP6955507B2 (ja) 2015-12-14 2021-10-27 マクロジェニクス，インコーポレーテッド Ｐｄ‐１及びｃｔｌａ‐４との免疫応答性を有する二重特異性並びにその使用方法
MA43773B1 (fr) * 2016-03-14 2026-01-30 Universitetet I Oslo Immunoglobulines génétiquement transformées ayant une liaison à fcrn altérée
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
CN110913954A (zh) 2017-03-03 2020-03-24 黑曜石疗法公司 免疫疗法的组合物和方法
CN110831961B (zh) 2017-03-03 2024-01-02 黑曜石疗法公司 用于免疫疗法的cd19组合物和方法
US20220403001A1 (en) 2018-06-12 2022-12-22 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
WO2020086742A1 (fr) 2018-10-24 2020-04-30 Obsidian Therapeutics, Inc. Régulation de protéine accordable par er
SG11202104373YA (en) * 2018-10-31 2021-05-28 Bioatla Inc Anti-ctla4 antibodies, antibody fragments, their immunoconjugates and uses thereof
SG11202106478UA (en) * 2019-01-03 2021-07-29 Invetx Inc Compositions for increasing half-life of a therapeutic agent in canines and methods of use
KR20210149251A (ko) 2019-03-08 2021-12-08 옵시디안 테라퓨틱스, 인크. 조율가능한 조절을 위한 인간 탄산 무수화효소 2 조성물 및 방법
WO2020227515A1 (fr) 2019-05-07 2020-11-12 Voyager Therapeutics, Inc. Compositions et méthodes d'augmentation vectorisée de la destruction, de l'expression et/ou de la régulation de protéines
EP4014050A1 (fr) 2019-08-12 2022-06-22 Voyager Therapeutics, Inc. Dosage immunologique à haute sensibilité pour la détection de la frataxine dans des liquides biologiques
US20230092895A1 (en) 2019-08-30 2023-03-23 Obsidian Therapeutics, Inc. Tandem cd19 car-based compositions and methods for immunotherapy
WO2021046451A1 (fr) 2019-09-06 2021-03-11 Obsidian Therapeutics, Inc. Compositions et méthodes de régulation de protéine accordable dhfr
EP4225787A4 (fr) * 2020-05-21 2024-10-23 Zydus Lifesciences Limited Variant fc et sa préparation
KR20230015365A (ko) 2020-05-22 2023-01-31 포르미콘 아게 Ace2 융합 단백질 및 이의 용도
US20240018499A1 (en) 2020-10-29 2024-01-18 Formycon Ag ACE2 Fusion Proteins and Uses Thereof
EP4301333A2 (fr) 2021-03-03 2024-01-10 Formycon AG Formulations de protéines de fusion ace2 fc
WO2023094507A1 (fr) 2021-11-24 2023-06-01 Formycon Ag Protéines de fusion ace2 améliorées
WO2023094571A1 (fr) 2021-11-25 2023-06-01 Formycon Ag Stabilisation de protéines de fusion ace2
EP4386084A1 (fr) 2022-12-14 2024-06-19 Formycon AG Protéines de fusion ace2 améliorées
WO2026039779A1 (fr) 2024-08-15 2026-02-19 Yale University Anticorps 3e10 humanisés et fragments de liaison à l'antigène optimisés pour la liaison rad51

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7361740B2 (en) * 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2004035752A2 (fr) * 2002-10-15 2004-04-29 Protein Design Labs, Inc. Modification d'affinites de liaison pour fcrn ou de demi-vies seriques d'anticorps par mutagenese
AU2003280247A1 (en) 2002-11-05 2004-06-07 Affinium Pharmaceuticals, Inc. Essential novel bacterial polypeptides
EP2368578A1 (fr) * 2003-01-09 2011-09-28 Macrogenics, Inc. Identification et ingénierie d'anticorps avec régions FC de variante et procédés d'utilisation associés
US7960512B2 (en) * 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US20090010920A1 (en) * 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
EP1673395A1 (fr) 2003-10-15 2006-06-28 PDL BioPharma, Inc. Modification de demi-vies seriques de proteines de fusion fc par mutagenese de positions 250, 314 et/ou 428 de la region constante de la chaine lourde des immunoglobulines
EP2385069A3 (fr) * 2003-11-12 2012-05-30 Biogen Idec MA Inc. Variantes de polypeptides Fc se liant au récepteur (FcRn) néonatal, protéines Fc dimèriques et procédés correspondants
MX2007000404A (es) * 2004-07-12 2008-03-04 Macrogenics Inc Identificacion de ingenieria de anticuerpos con regiones de fc variante y metodos para usar las mismas.
EP3342782B1 (fr) * 2004-07-15 2022-08-17 Xencor, Inc. Variantes optimisées de fc
WO2007024249A2 (fr) 2004-11-10 2007-03-01 Macrogenics, Inc. Fonction effectrice obtenue par creation par genie biologique de regions d'anticorps fc
BRPI0517837A (pt) 2004-11-12 2008-10-21 Xencor Inc variantes fc com ligação alterada a fcrn
US8802820B2 (en) * 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
WO2006104989A2 (fr) * 2005-03-29 2006-10-05 Verenium Corporation Anticorps a regions fc modifiees et utilisations
HUE029465T2 (en) * 2005-08-10 2017-02-28 Macrogenics Inc Identification and engineering of antibodies with variant Fc regions and methods of using same
EP1943332A4 (fr) * 2005-10-14 2011-04-13 Medimmune Inc Affichage cellulaire de libraires d'anticorps
AU2008345242B2 (en) * 2007-10-31 2014-02-27 Xencor, Inc. Fc variants with altered binding to FcRn
CA2726845C (fr) * 2008-06-04 2017-09-26 Macrogenics, Inc. Anticorps a liaison alteree a fcrn et leurs procedes d'utilisation
BRPI1006998A2 (pt) 2009-01-23 2015-08-25 Biogen Idec Inc Polipeptídeos fc estabilizados com função efetora reduzida e métodos de uso
LT2975051T (lt) 2009-06-26 2021-07-12 Regeneron Pharmaceuticals, Inc. Lengvai išskiriami bispecifiniai antikūnai su natyvios formos imunoglobulinu
TWI667257B (zh) * 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體
US8735546B2 (en) * 2010-08-03 2014-05-27 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
US8483058B2 (en) 2010-08-17 2013-07-09 Qualcomm Incorporated Systems and methods for traffic policing
EP2731781B1 (fr) 2011-07-15 2016-05-18 Basell Poliolefine Italia S.r.l. Lanière de polyoléfine contenant un copolymère aléatoire de propylène avec 1-hexène
SG11201401102VA (en) * 2011-09-30 2014-09-26 Chugai Pharmaceutical Co Ltd Ion concentration-dependent binding molecule library
CN104204217A (zh) * 2012-01-19 2014-12-10 医用蛋白国际有限责任公司 抗cd20抗体利妥昔单抗的稳定化

Also Published As

Publication number Publication date
US20180186863A1 (en) 2018-07-05
US10954288B2 (en) 2021-03-23
JP6470170B2 (ja) 2019-02-13
EP3470433A1 (fr) 2019-04-17
CA2871807A1 (fr) 2013-10-31
MX382840B (es) 2025-03-13
EP3470433C0 (fr) 2025-12-03
MX2014012978A (es) 2015-02-05
US20150065690A1 (en) 2015-03-05
AU2013251309B2 (en) 2017-06-22
KR20150008082A (ko) 2015-01-21
CN104428317B (zh) 2018-08-28
AU2017225111B2 (en) 2019-01-03
CN104428317A (zh) 2015-03-18
AU2017225111A1 (en) 2017-09-28
BR112014026740A8 (pt) 2021-06-15
CA2871807C (fr) 2022-10-04
BR112014026740B1 (pt) 2022-10-04
AU2019202229B2 (en) 2021-02-11
AU2013251309A1 (en) 2014-10-30
JP2015515497A (ja) 2015-05-28
EP3470433B1 (fr) 2025-12-03
RU2014147741A (ru) 2016-06-20
AU2019202229A1 (en) 2019-04-18
WO2013163630A1 (fr) 2013-10-31
KR20200037434A (ko) 2020-04-08
EP2841458A4 (fr) 2015-09-16
MX360368B (es) 2018-10-29
BR112014026740A2 (pt) 2017-06-27
EP2841458A1 (fr) 2015-03-04
HK1207654A1 (en) 2016-02-05

Similar Documents

Publication Publication Date Title
MX360368B (es) Regiones de anticuerpo modificado y sus usos.
MX2022000026A (es) Anticuerpos para tau.
MX2015006324A (es) Metodos para la fabricacion de polipeptidos proteoliticamente procesados.
PH12014501427B1 (en) Anti-phf-tau antibodies and their uses
PH12015502565B1 (en) Anti-transferrin receptor antibodies and methods of use
PH12014502132A1 (en) Anti-lgr5 antibodies and immunoconjugates
MX2016003129A (es) Terapia de combinacion de anticuerpos contra el csf-1r humano y anticuerpos contralel pd-l1 humano.
IN2014DN05885A (fr)
PH12015501059A1 (en) Anti-hemagglutinin antibodies and methods of use
EA201590993A1 (ru) Гетеродимерные иммуноглобулины
MX342240B (es) Anticuerpos anti-fgfr4 y metodos de uso.
MX2014002053A (es) Anticuerpos anti -mcsp y metodos de uso.
MX2013001473A (es) Anticuerpos contra il-18r1 y usos de los mismos.
PH12012501493A1 (en) Anticoagulant antidotes
PH12014500841B1 (en) ANTI-HtrA1 ANTIBODIES AND METHODS OF USE
MX354303B (es) Anticuerpos de anti-biotina y metodos de uso.
MX357675B (es) Anticuerpos anti-jagged y métodos de uso.
TN2013000388A1 (en) Anticoagulant antidotes
MX2014014381A (es) Anticuerpos de anti-teofilina y metodos de uso.
UA117567C2 (uk) Композиція, яка стимулює лактацію, на основі фосфатидилсерину
MX2015010789A (es) Anticuerpos anti-pcsm.
UA80618U (en) Use of n-steroylethanolamine as radiomodifier
AU345983S (en) Cosmetic cases and cosmetic kits
UA106373C2 (ru) Применение поллентара как средства фригопротекторного действия